English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  A data- and model-drivenapproach for cancer treatment

Schade, S., Ogilvie, L. A., Kessler, T., Schütte, M., Wierling, C., Lange, B. M., et al. (2019). A data- and model-drivenapproach for cancer treatment. Der Onkologe, 25(Suppl. 2), S132-S137. doi:10.1007/s00761-019-0624-z.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0006-3AEE-E Version Permalink: http://hdl.handle.net/21.11116/0000-0006-3AEF-D
Genre: Journal Article

Files

show Files
hide Files
:
Schade_2019.pdf (Publisher version), 2MB
Name:
Schade_2019.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
© The Author(s) 2019

Locators

show

Creators

show
hide
 Creators:
Schade, Sophia1, Author
Ogilvie, Lesley A. 1, Author
Kessler, Thomas1, Author
Schütte, Moritz1, Author
Wierling, Christoph1, Author
Lange, Bodo M.1, Author
Lehrach, Hans1, 2, Author              
Yaspo, Marie-Laure1, 3, Author              
Affiliations:
1Alacris Theranostics GmbH, Berlin, Deutschland, ou_persistent22              
2Emeritus Group of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_2385697              
3Gene Regulation and Systems Biology of Cancer (Marie-Laure Yaspo), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_2117287              

Content

show
hide
Free keywords: Precision medicine · Biomarkers, Tumor · Geneexpression profiling · Translational medicalresearch · Molecular targeted therapy
 Abstract: All people are unique and so are their diseases. Our genomes, disease histories, behavior, and lifestyles are all different; therefore it is not too surprising that people often respond differently when administered the same drugs. Cancer, in particular, is a complex and heterogeneous disease, originating in patients with different genomes, in cells with the different epigenomes, formed and evolving on the basis of random processes, with the response to therapy not only depending on the individual cancer cell but also on many features of the patient. Selection of an optimal therapy will therefore require a deep molecular analysis comprising both the patient and their tumor (e.g., comprehensive molecular tumor analysis [CMTA]), and much better personalized prediction of response to possible therapies. Currently, we are at an inflection point in which advances in technology, decreases in the costs of sequencing and other molecular analyses, and increases in computing advances are converging, forming the foundation to build a data-driven approach to personalized oncology. In this article we discuss the deep molecular characterization of individual tumors and patients as the basis of not only current precision oncology but also of computational models (‘digital twins’), the foundation for a truly personalized therapy selection of the future. We are all very different, with different genomes, different disease histories, different behavior and molecularly different diseases. It is therefore not surprising that we often react differently to drugs we receive. To overcome this in oncology, we require much deeper data on individual tumors and patients (e.g., comprehensive molecular tumor analysis, CMTA), and much better personalized prediction of the effects of possible therapies, initially through precision medicine, but increasingly through digital models of individual tumors and patients, our “digital twins”.

Details

show
hide
Language(s): eng - English
 Dates: 2019-08-27
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.1007/s00761-019-0624-z
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Der Onkologe
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Heidelberg : Springer Medizin Verlag GmbH
Pages: 6 Volume / Issue: 25 (Suppl. 2) Sequence Number: - Start / End Page: S132 - S137 Identifier: ISSN: 0947-8965 (print)
ISSN: 1433-0415 (electronic)